JP7620002B2 - ヘテロタンデム二環式ペプチド複合体 - Google Patents

ヘテロタンデム二環式ペプチド複合体 Download PDF

Info

Publication number
JP7620002B2
JP7620002B2 JP2022506077A JP2022506077A JP7620002B2 JP 7620002 B2 JP7620002 B2 JP 7620002B2 JP 2022506077 A JP2022506077 A JP 2022506077A JP 2022506077 A JP2022506077 A JP 2022506077A JP 7620002 B2 JP7620002 B2 JP 7620002B2
Authority
JP
Japan
Prior art keywords
acid
peptide
pharma
complex
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506077A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021019243A5 (enExample
JP2022542386A (ja
Inventor
マクドネル ケビン
ウパディヤヤ プニット
ラーデンランタ ジョハンナ
マッド ジェマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2022542386A publication Critical patent/JP2022542386A/ja
Publication of JPWO2021019243A5 publication Critical patent/JPWO2021019243A5/ja
Application granted granted Critical
Publication of JP7620002B2 publication Critical patent/JP7620002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022506077A 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体 Active JP7620002B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962880191P 2019-07-30 2019-07-30
US62/880,191 2019-07-30
US201962910088P 2019-10-03 2019-10-03
US62/910,088 2019-10-03
US201962931442P 2019-11-06 2019-11-06
US62/931,442 2019-11-06
US202063022667P 2020-05-11 2020-05-11
US63/022,667 2020-05-11
US202063024715P 2020-05-14 2020-05-14
US63/024,715 2020-05-14
PCT/GB2020/051827 WO2021019243A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Publications (3)

Publication Number Publication Date
JP2022542386A JP2022542386A (ja) 2022-10-03
JPWO2021019243A5 JPWO2021019243A5 (enExample) 2023-08-08
JP7620002B2 true JP7620002B2 (ja) 2025-01-22

Family

ID=71948620

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2022506077A Active JP7620002B2 (ja) 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体
JP2022505570A Active JP7704732B2 (ja) 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体
JP2022505581A Active JP7682852B2 (ja) 2019-07-30 2020-07-30 ＥｐｈＡ２に特異的な二環式ペプチドリガンド
JP2022506048A Active JP7579840B2 (ja) 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体
JP2025080947A Pending JP2025122030A (ja) 2019-07-30 2025-05-14 ＥｐｈＡ２に特異的な二環式ペプチドリガンド

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022505570A Active JP7704732B2 (ja) 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体
JP2022505581A Active JP7682852B2 (ja) 2019-07-30 2020-07-30 ＥｐｈＡ２に特異的な二環式ペプチドリガンド
JP2022506048A Active JP7579840B2 (ja) 2019-07-30 2020-07-30 ヘテロタンデム二環式ペプチド複合体
JP2025080947A Pending JP2025122030A (ja) 2019-07-30 2025-05-14 ＥｐｈＡ２に特異的な二環式ペプチドリガンド

Country Status (15)

Country Link
US (7) US11312749B2 (enExample)
EP (4) EP4003528A1 (enExample)
JP (5) JP7620002B2 (enExample)
KR (3) KR20220054309A (enExample)
CN (4) CN114502598A (enExample)
AU (3) AU2020319704B2 (enExample)
BR (3) BR112022001521A2 (enExample)
CA (3) CA3147570A1 (enExample)
IL (3) IL290090A (enExample)
MX (3) MX2022001288A (enExample)
MY (2) MY208496A (enExample)
PH (2) PH12022550173A1 (enExample)
SA (2) SA522431587B1 (enExample)
TW (2) TWI862640B (enExample)
WO (4) WO2021019246A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN119192401A (zh) * 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
MX2024002098A (es) * 2021-08-17 2024-03-05 Medshine Discovery Inc Conjugado farmaco-polipeptido con estructura innovadora y su aplicacion.
JP7774349B2 (ja) * 2021-09-29 2025-11-21 星聯▲タイ▼（珠海）生物科技有限公司 三環式ポリペプチド複合体薬物及びその使用
JP2024543505A (ja) * 2021-11-16 2024-11-21 バイスクルテクス・リミテッド 癌の治療方法
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
WO2024229427A1 (en) * 2023-05-04 2024-11-07 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
WO2025191096A1 (en) * 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
WO2025248261A1 (en) 2024-05-31 2025-12-04 Bicycletx Limited Method for identifying patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
WO2019122860A1 (en) 2017-12-19 2019-06-27 Bicycletx Limited Bicyclic peptide ligands specific for epha2
WO2019193328A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
CA2345376C (en) 1998-09-24 2010-03-16 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and bioconjugates thereof
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
DE60325740D1 (de) 2002-08-14 2009-02-26 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
JP2006514104A (ja) 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
WO2006101187A1 (en) 2005-03-22 2006-09-28 Rohto Pharmaceutical Co., Ltd. Peptides that increase collagen or hyaluronic acid production
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2621502A1 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN101282948A (zh) 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
MX2009002775A (es) 2006-09-15 2009-06-17 Siemens Medical Solutions Derivados de ciclopeptido de quimica click como agentes de formacion de imagen para integrinas.
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
EP2155177A2 (en) 2007-04-30 2010-02-24 Intezyne Technologies Incorporated Modification of biological targeting groups for the treatment of cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN101918844A (zh) 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
KR101595138B1 (ko) 2008-02-27 2016-02-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 괴사종양의 광역학요법 및 영상용 알지디(박테리오)클로로필 컨쥬게이트
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
CA2769444A1 (en) 2009-05-19 2010-11-25 Aic Blab Company Composite current collector and methods therefor
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011079015A1 (en) 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
JP2013518807A (ja) 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
CN103906865B (zh) 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
JP6321658B2 (ja) 2012-09-24 2018-05-09 メディミューン リミテッド アミノ酸誘導体
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
CN118146306A (zh) 2013-09-25 2024-06-07 西托姆克斯治疗公司 基质金属蛋白酶底物和其它可切割部分及其使用方法
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
AU2015255883A1 (en) 2014-05-08 2016-10-27 Novodiax, Inc. Direct immunohistochemistry assay
CN113861268B (zh) 2014-05-21 2025-04-01 恩特拉达治疗学股份有限公司 细胞穿透肽及其制备和使用方法
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
WO2016050361A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
AU2015335725B2 (en) 2014-10-24 2021-06-03 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to EphA2 receptor
SI3215518T1 (sl) * 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
CN107406463A (zh) 2014-12-04 2017-11-28 细胞基因公司 生物分子共轭物
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3287027B1 (en) 2015-04-22 2021-07-28 Mitsui Chemicals, Inc. Clothing provided with joint supporter portion, and knee supporter
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
EP3288962A1 (en) 2015-04-28 2018-03-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Novel inhibitors of the enzyme activated factor xii (fxiia)
CN107849116A (zh) 2015-05-06 2018-03-27 詹森生物科技公司 前列腺特异性膜抗原结合iii型纤连蛋白结构域
RU2754466C2 (ru) * 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
EP3429630A1 (en) 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MY197235A (en) * 2016-04-20 2023-06-07 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017182672A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
EP3559019A1 (en) 2016-12-23 2019-10-30 BicycleTX Limited Peptide ligands for binding to mt1-mmp
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2018222987A1 (en) 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
EP3870597A1 (en) 2018-10-23 2021-09-01 BicycleTx Limited Bicyclic peptide ligands and uses thereof
CA3116504A1 (en) 2018-10-30 2020-05-07 Bicyclerd Limited Bt1718 for use in treating cancer
JP2022513806A (ja) 2018-12-13 2022-02-09 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (en) 2019-08-13 2022-06-22 BicycleTX Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
CN119192401A (zh) 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20220387611A1 (en) 2019-10-16 2022-12-08 Bicyclerd Limited Methods for treating cancer
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
KR20230037502A (ko) 2020-05-20 2023-03-16 바이사이클티엑스 리미티드 넥틴-4에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
AU2021289095A1 (en) 2020-06-12 2023-01-05 Bicycletx Limited Treatment of diseases characterized by overexpression of Erythropoietin-producing hepatocellular receptor A2 (EphA2)
WO2022029420A1 (en) 2020-08-03 2022-02-10 Bicycletx Limited Peptide-based linkers
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
AU2022206577A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
AU2022206394A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
WO2022148969A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
IL310795A (en) 2021-09-03 2024-04-01 Bicycletx Ltd Synthesis of bicycle toxin conjugates, and intermediates thereof
JP2024543505A (ja) 2021-11-16 2024-11-21 バイスクルテクス・リミテッド 癌の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
WO2019122860A1 (en) 2017-12-19 2019-06-27 Bicycletx Limited Bicyclic peptide ligands specific for epha2
WO2019193328A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes

Also Published As

Publication number Publication date
KR20220051345A (ko) 2022-04-26
US12435107B2 (en) 2025-10-07
KR20220054309A (ko) 2022-05-02
US11306123B2 (en) 2022-04-19
TW202118770A (zh) 2021-05-16
WO2021019244A1 (en) 2021-02-04
CA3147570A1 (en) 2021-02-04
JP2022542286A (ja) 2022-09-30
CN114341190A (zh) 2022-04-12
BR112022001521A2 (pt) 2022-07-12
AU2020319704B2 (en) 2025-08-14
US20210069287A1 (en) 2021-03-11
US20240336656A1 (en) 2024-10-10
SA522431587B1 (ar) 2024-04-24
US20220257784A1 (en) 2022-08-18
IL290093A (en) 2022-03-01
JP2025122030A (ja) 2025-08-20
US11312749B2 (en) 2022-04-26
JP7682852B2 (ja) 2025-05-26
JP2022544058A (ja) 2022-10-17
IL290090A (en) 2022-03-01
WO2021019243A1 (en) 2021-02-04
JP7704732B2 (ja) 2025-07-08
CN114555626B (zh) 2025-04-08
US11970553B2 (en) 2024-04-30
MY208496A (en) 2025-05-13
EP4003530A1 (en) 2022-06-01
CN114521197A (zh) 2022-05-20
PH12022550173A1 (en) 2022-11-14
US20220227811A1 (en) 2022-07-21
TW202110485A (zh) 2021-03-16
MX2022001288A (es) 2022-02-22
CN114521197B (zh) 2025-04-11
CA3148033A1 (en) 2021-02-04
US20210040154A1 (en) 2021-02-11
JP2022542386A (ja) 2022-10-03
TWI860386B (zh) 2024-11-01
AU2020323739B2 (en) 2025-11-06
MY208497A (en) 2025-05-13
US20230129258A1 (en) 2023-04-27
AU2020322193A1 (en) 2022-03-17
CN114555626A (zh) 2022-05-27
CA3148039A1 (en) 2021-02-04
EP4003529A1 (en) 2022-06-01
EP4003528A1 (en) 2022-06-01
KR20220049529A (ko) 2022-04-21
WO2021019246A1 (en) 2021-02-04
IL290089A (en) 2022-03-01
CN114502598A (zh) 2022-05-13
AU2020319704A1 (en) 2022-03-17
EP4003527A1 (en) 2022-06-01
BR112022001520A2 (pt) 2022-06-21
PH12022550171A1 (en) 2023-05-15
US20220242911A1 (en) 2022-08-04
AU2020323739A1 (en) 2022-03-17
MX2022001273A (es) 2022-02-22
BR112022001532A2 (pt) 2022-06-07
TWI862640B (zh) 2024-11-21
MX2022001290A (es) 2022-02-22
JP7579840B2 (ja) 2024-11-08
SA522431586B1 (ar) 2024-04-24
WO2021019245A1 (en) 2021-02-04
JP2022542291A (ja) 2022-09-30

Similar Documents

Publication Publication Date Title
JP7620002B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7551500B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7404241B2 (ja) ＥｐｈＡ２に特異的な二環ペプチドリガンド
CN111183147B (zh) Cd137特异性的双环肽配体
JP2024023291A (ja) 多量体二環式ペプチドリガンド
CA3154672A1 (en) Bicyclic peptide ligand drug conjugates
JP7645801B2 (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2025011099A (ja) Ｐｓｍａに特異的な二環式ペプチドリガンド
CN113383007A (zh) Caix特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
EA046294B1 (ru) Гетеротандемный бициклический пептидный комплекс
EA046193B1 (ru) Гетеротандемный бициклический пептидный комплекс

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250109

R150 Certificate of patent or registration of utility model

Ref document number: 7620002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150